Schizophrenia

Completed Programs, Program

Psychiatric GWAS Consortium

The overarching goal of the consortium is to conduct a rigorous set of analyses of GWAS data for Attention Deficit Hyperactivity Disorder, autism, bipolar disorder, major depression disorder, and schizophrenia, utilizing the knowledge and capabilities of the contributing groups to accomplish analyses that can help move the entire field of mental health genetic research forward.

Program, Research Partners

Measures for Clinical Trials of Treatment of Cognitive Impairment (MATRICS-CT)

Schizophrenia is a chronic, severe brain disorder that affects over one percent of the U.S. population. Because many sufferers have difficulty holding a job or caring for themselves, the burden on their families and society is significant. Current treatments fall short of relieving many symptoms.

Completed Programs, Past Programs

Schizophrenia Metabolic Initiative (SMI)

The goal of this multi-year project is to evaluate schizophrenia medications as they relate to indicators for cardiovascular disease and disease stability, and to determine treatment effectiveness.

Donate button

Related News
The Cultural Adaptability of Intermediate Measures of Functional Outcome in Schizophrenia

Related Topics